$10,000 to Invest? Coca-Cola or Johnson & Johnson- One Stock Is More Reliable

• Johnson & Johnson (JNJ) reported Q4 gross of $24.56B, up 9.1% YoY, with Innovative Medicine generating $15.76B and oncology cause DARZALEX surging 26.6% to $3.90B.

• Coca-Cola (KO) reported Q4 gross of $11.82B, missing statement by 2.7%, portion Zero Sugar posted 13% portion lawsuit measurement maturation and the institution took a $960M BODYARMOR impairment.

• J&J is aggressively reshaping its portfolio done acquisitions and spinoffs portion investing $55B successful biotech pipelines, whereas Coca-Cola is moving toward an asset-light exemplary done refranchising, with some companies facing chiseled maturation challenges: J&J indispensable offset STELARA biosimilar erosion portion Coca-Cola indispensable prolong pricing powerfulness amid measurement declines successful Asia Pacific.

• If you're focused connected picking the close stocks and ETFs you whitethorn beryllium missing the bigger picture: status income. That is precisely what The Definitive Guide to Retirement Income was created to solve, and it's escaped today. Read much here

Johnson & Johnson closed the 4th fourth with $24.56B successful revenue, up 9.1% twelvemonth implicit year, beating the statement estimation of $24.13B. Innovative Medicine generated $15.76B, up 10%.

If you're focused connected picking the close stocks and ETFs you whitethorn beryllium missing the bigger picture: retirement income. That is precisely what The Definitive Guide to Retirement Income was created to solve, and it's escaped today. Read much here

DARZALEX reached $3.90B successful the quarter, up 26.6%. TREMFYA surged 67.6% to $1.58B. CAR-T therapy CARVYKTI climbed 65.8% to $555M. CEO Joaquin Duato called 2025 "a catapult twelvemonth for Johnson & Johnson, fueled by the strongest portfolio and pipeline successful our history."

Coca-Cola's gross came successful astatine $11.82B, missing the $12.15B statement by 2.7%, portion integrated gross grew 5%. Currency headwinds and refranchising distort the headline. Coca-Cola Zero Sugar posted portion lawsuit measurement maturation of 13% successful Q4 and 14% for the afloat year.

Johnson & Johnson is reshaping itself aggressively: spinning disconnected its DePuy Synthes orthopaedics unit, completing the acquisition of Intra-Cellular Therapies (maker of CAPLYTA) successful April 2025, and submitting its OTTAVA robotic surgical strategy to the FDA.